Patents Issued in December 19, 2017
  • Patent number: 9844498
    Abstract: The invention relates to a method of manufacturing a cosmetic article having a decorative embossed and/or debossed surface, based on at least one cosmetic product hot-poured into a container, this method making use of: a receptacle forming said container and having a peripheral wall and a bottom, said receptacle having at least one filling area, each filling area extending from the bottom of said receptacle and having a filling hole and at least one vent hole, and a closure member that cooperates with the receptacle to define an enclosed filling cavity with the at least one filling area, and having an embossed and/or debossed surface adapted to give the cosmetic product poured into said cavity an embossed and/or debossed surface, said method comprising at least the following steps: a) positioning the receptacle on the closure member so that the embossed and/or debossed surface extends into the filling area; b) hot-injecting the cosmetic product into the filling cavity by means of a filling head inserted in th
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: December 19, 2017
    Assignee: PARFUMS CHRISTIAN DIOR
    Inventors: Emeric Baracat-Nasr, Xiaolu He
  • Patent number: 9844499
    Abstract: A solid composition comprising: (a) an aminosilicone polymer, wherein the aminosilicone polymer comprises amino sidechains, and wherein the aminosilicone polymer has a weight average molecular weight of from 10,000 Dalton to 60,000 Dalton; (b) a silicone resin; (c) an ether of a water-soluble polyhydric alcohol; (d) one or more pigments or one or more colored materials; (e) a thickening system comprising: a deposition enhancer, wherein the deposition enhancer is a hydrophilic and non-ionic polymer, and wherein the deposition enhancer has a weight average molecular weight of from 700,000 Dalton to 3,000,000 Dalton; and a thickening polymer, wherein the thickening polymer has a weight average molecular weight of at least 10,000 Dalton, and wherein the thickening polymer is a cationic thickening polymer or is a non-ionic thickening polymer. Also associated methods, kits and uses.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 19, 2017
    Assignee: Noxell Corporation
    Inventors: Mathias Kurt Herrlein, Tatjana Schaefer, Andreas Flohr, Rosalind Mary Holmes, Marianna Forgione, Matija Crne, Yonas Gizaw, Ursula Christina Glaser
  • Patent number: 9844500
    Abstract: The process of the invention provides for a preventive hair treatment with buffering agent, in particular glyoxylic acid in combination with mechanical straightening with hair straightening iron at temperature of approximately 200° C.+/?50° C.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: December 19, 2017
    Assignee: KAO CORPORATION
    Inventor: Alderano Mannozzi
  • Patent number: 9844501
    Abstract: Described herein is a hair color composition for dyeing the hair. The hair color composition includes one or more direct dye compounds and one or more additional ingredients. The one or more direct dye compounds each include a chromophore, one or two permanent cations, one to four incipient cations, and one or more hydrophobic moieties. The incipient cations are pendant to the core structure and are neutral. The one or more direct dye compounds enter the hair shaft after the hair color composition is applied to the hair. The hair color composition has a pH of from about 7 to about 11.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Noxell Corporation
    Inventors: Guiru Zhang, Bryan Patrick Murphy, Peter Marte Torgerson
  • Patent number: 9844502
    Abstract: A make-up composition is for the skin, is prepared by a process and used in a makeup method. The cosmetic composition is intended for making up the skin. The composition has from 75 to 98% by weight of a powder or a mixture of powders, as well as at least one cosmetically acceptable fatty phase having at least one oil. The composition additionally includes a block copolymer of at least one styrene polymer and of at least one olefin polymer, the olefin being other than styrene, or a mixture of these block copolymers.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 19, 2017
    Assignee: LVMH RECHERCHE
    Inventors: Sabine Vic, Murielle Farigoule, Brigitte Noe, Eric Perrier
  • Patent number: 9844503
    Abstract: Disclosed is a composition and method for its use that includes Magnolia bark extract, vitis vinifera extract, tocopherol or tocopherol acetate, and hydrogenated lecithin, lecithin, or dextrin.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: December 19, 2017
    Assignee: Mary Kay Inc.
    Inventors: Jim Faller, David Gan, Michelle Hines, Lisa Mangos
  • Patent number: 9844504
    Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: December 19, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Flordeliza Villanueva, Andrew Carson, Charles F. McTiernan, Jianjun Wang
  • Patent number: 9844505
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 19, 2017
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 9844506
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, e.g., for affecting mood states. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 19, 2017
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9844508
    Abstract: The invention provides a tumor vaccine and method for producing the same. The tumor vaccine comprises cell vesicles derived from apoptotic tumor cells and an adjuvant. The invention further provides a preparation method of the tumor vaccine, comprising the steps of using the UV to irradiate the tumor cells to induce apoptosis, and collecting the cell vesicles released from the apoptotic tumor cells and then mixing the cell vesicles with the adjuvant to form the tumor vaccine. The tumor vaccine provided by the invention contains a broad and comprehensive tumor antigen spectrum, the defect that the existing tumor vaccine cannot have the killing capacity against the broad tumor cells can be overcome, and at the same time the tumor vaccine has good use safety and immune targeting property.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: December 19, 2017
    Assignee: HUBEI SOUNDNY BIOTECHNOLOGY CO., LTD.
    Inventor: Bo Huang
  • Patent number: 9844509
    Abstract: This application provides a high throughput method of making nanoparticles that utilizes plates comprising wells (e.g., 96-well plates).
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: December 19, 2017
    Assignee: PFIZER INC.
    Inventor: David M. Dewitt
  • Patent number: 9844510
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Laboratoire HRA-Pharma
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Patent number: 9844511
    Abstract: The invention relates to a coating composition suitable for the coating of a pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process, wherein either the core of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer or vice versa.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: December 19, 2017
    Assignee: Evonik Roehm GmbH
    Inventors: Kathrin Nollenberger, Jan Hendrik Schattka, Rene Leubert, Florian Hermes, Manfred Assmus, Christian Meier, Thomas Dassinger, Thomas Riermeier
  • Patent number: 9844512
    Abstract: A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: December 19, 2017
    Assignee: CATALENT ONTARIO LIMITED
    Inventors: Peter Robert Draper, James Edward Draper, Beth Marie Okutan
  • Patent number: 9844513
    Abstract: The present application provides a method for treating or preventing Celiac disease. In one embodiment the method comprises administering to a patient in need thereof a composition comprising minicapsules, wherein the minicapsules comprise a steroid in a liquid, semi-solid or solid core, the minicapsules having release profiles to release the steroid in an active form at one or more sites along the gastrointestinal tract, the one or more sites comprising the proximal small intestine beginning at the duodenum and ending at the ileum. In a related embodiment the method comprises administering budesonide to a patient in need thereof in a pre-solubilized drug delivery format.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: December 19, 2017
    Assignee: Sigmoid Pharma Limited
    Inventor: Ivan Coulter
  • Patent number: 9844514
    Abstract: This application discloses methods for treating an established myocardial infarction, including treatment with an epicardial construct containing stromal vascular fraction (SVF) from adipose tissue which may be seeded onto a biocompatible substrate, which preserves microvascular function and LV contractile mechanisms.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: December 19, 2017
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Stuart K. Williams, James B. Hoying, Amanda J. LeBlanc
  • Patent number: 9844515
    Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: December 19, 2017
    Assignee: Hexal AG
    Inventors: Jens Fleschhut, Susanne Feinaeugle, Karin Lauer
  • Patent number: 9844516
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 19, 2017
    Assignee: Laboratorios De Dr. Esteve
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
  • Patent number: 9844517
    Abstract: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: December 19, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Chron-Si Lai, John B. Lasekan, Gary E. Katz, Christopher T. Cordle
  • Patent number: 9844518
    Abstract: This invention is directed to a method of growing a plant from the Cannabaceae family, the cultivar or composition produced therefrom, wherein the plant is exposed to artificial lighting of different intensities based on spacing, growth phase, and flowering yield.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: December 19, 2017
    Assignee: MJAR Holdings, LLC
    Inventors: James Lowe, Benjamin Franz, Matthew Curran
  • Patent number: 9844519
    Abstract: A method of treating TDP-43 proteinopathies such as Alzheimer's disease, amyotrophic lateral sclerosis, and fronto-temporal lobar dementia is presented herein. It was found that administering hexachlorophene to cells expressing endogenous TDP-43 or overexpressing wild-type TDP-43 reduced accumulation of TDP-43 in the cells.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: December 19, 2017
    Assignee: University of South Florida
    Inventors: Umesh K. Jinwal, Diego A. Peralta, Malathi Narayan
  • Patent number: 9844520
    Abstract: Described herein, inter alia, are compositions, formulations, methods, and systems for reducing regional fat deposits and treating fat-related conditions.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: December 19, 2017
    Inventor: John Daniel Dobak, III
  • Patent number: 9844521
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating learning disorders, memory disorders, Parkinson's disease, or ischemic cerebrovascular disease, which comprises a ginger extract or shogaol; and a pharmaceutically acceptable carrier. And also, the present invention provides a food composition for improving learning disorders or memory disorders or alleviating the symptoms of learning disorders or memory disorders which comprises a ginger extract or shogaol as an active ingredient, or a food composition for improving learning or memory which comprises a ginger extract or shogaol as an active ingredient.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: December 19, 2017
    Assignee: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Sun-Yeou Kim, Sang-Keun Ha, Jong-Hoon Ryu, Myung-Sook Oh, Seo-Young Jeong
  • Patent number: 9844522
    Abstract: The present invention relates to novel therapeutic uses of niclosamide for the treatment of cancer. In particular, a combination of niclosamide or one of its derivatives with an alkylating agent is provided for the treatment of solid tumors. Moreover, niclosamide or one of its derivatives can be used for the treatment of solid tumors characterized by underexpression of NFKBIA. Finally, the invention relates to diagnostic methods for determining whether treatment with niclosamide alone or in combination with an alkylating agent is suitable for a cancer patient.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: December 19, 2017
    Assignees: LIFE & BRAIN GMBH, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT BONN
    Inventors: Björn Scheffler, Martin Glas, Anja Wieland
  • Patent number: 9844523
    Abstract: Disclosed is a lactic acid-containing composition for inducing animal ovarian dysfunction, designed to increase meat production by causing ovarian dysfunction within animals. The composition comprises 10 to 90% by weight of lactic acid and 10 to 90% by weight of an adjuvant, having a pH of 1˜5. When locally injected into the ovary, the composition causes the ovarian tissue to lose its function, suppressing the estrus of the animals that thus improve in growth and appetite, with a consequent increase in meat production. Also, because even one injection of the lactic acid-based composition at a small dose can accomplish ovarian dysfunction, no lactic acid is left in the meat as well as the animals. Moreover, the composition, even though administered, does not require a drug-free interval, nor cause an increase in blood lactic acid level, and thus can produce animal products suitable for hormone-free certification.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 19, 2017
    Assignee: Navibiotech Co. Ltd.
    Inventors: Jung Moon Ko, Jun Jeong, Ki Se Lee
  • Patent number: 9844524
    Abstract: Natural soap compositions and methods of manufacturing the same having anti-microbial properties for treating and preventing diaper rash and other microbial infections. The soap compositions may contain one or more fatty acids with carbon length ranging from four (C4) to twenty-two (C22) and/or natural fatty acid mixtures of coconut oil, olive oil, and/or tall oil fatty acids which are saponified with lye. The saponification lye may be sodium or potassium hydroxide. In preferred embodiments, the soap compositions contain at least one of sodium or potassium caprate, sodium or potassium caprylate, or mixtures thereof, especially 55:45% caprylate to caprate. The soap compositions are effective at treating or preventing diaper rashes and other microbial infections associated with Candida albicans (Ca—yeast), Pseudomonas aeruginosa (Psa—a Gram negative bacteria), Staphylococcus aureus (Sa—a Gram positive bacteria), and Aspergillus niger (An—a mold).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: December 19, 2017
    Assignee: VANGUARD SOAP LLC
    Inventor: Scott A. Smith
  • Patent number: 9844525
    Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B 12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: December 19, 2017
    Assignee: N.V. Nutricia
    Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
  • Patent number: 9844526
    Abstract: Methods of increasing the plasma concentration of resveratrol in a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 19, 2017
    Assignee: Gateway Health Alliances, Inc.
    Inventors: Shil Kothari, Gary Troxel
  • Patent number: 9844528
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 19, 2017
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Thamarai Ponnusamy, Ramesh Narayanan
  • Patent number: 9844529
    Abstract: The present invention provides a method of treating ovarian cancer in a mammal in need of such treatment comprising administering an effective amount of a combination of gemcitabine, cisplatin or carboplatin, and 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: December 19, 2017
    Assignee: Eli Lilly and Company
    Inventors: Edward Michael Chan, Susan Elizabeth Pratt, Louis Frank Stancato
  • Patent number: 9844530
    Abstract: This invention generally relates to methods of treatment of glaucoma and symptomatic relief of conjunctival inflammation. An ophthalmic solution comprising cannabinoids for the treatment of glaucoma and an ophthalmic solution comprising cannabinoids for these purposes are disclosed. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 19, 2017
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George Anastassov, Lekhram Changoer
  • Patent number: 9844531
    Abstract: Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 19, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Sean Garvey, Suzette Pereira, Neile Edens
  • Patent number: 9844532
    Abstract: This invention relates to a method of improving CNS maturation in an infant by administering a mixture of natural tocopherols, wherein the composition contains an optimum tocopherol profile similar to that found in human breast milk, and can encompass a tocopherol profile from early stage to transitional to mature human breast milk. For ease of administration and maximized efficacy, the optimized mixture of natural tocopherols are typically delivered in an oral dosage form with a limited level of non-RRR alpha-tocopherols to maximize efficacy of the RRR alpha-tocopherol on stimulating post-natal CNS development.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Abbott Laboratories
    Inventors: Chron-Si Lai, Matthew Kuchan, Gary Katz
  • Patent number: 9844533
    Abstract: The invention encompasses methods for inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. The compositions and methods of the invention include an amount of lipoic acid that is effective in inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: December 19, 2017
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Jeffrey A. Brockman, Steven C. Zicker
  • Patent number: 9844534
    Abstract: The invention is directed to compounds that are specific inhibitors of PKC delta, and methods and compositions for the treatment and prevention of cancers and other disorders. Compositions comprising compounds of the invention are used to treat cancers such as, for example, carcinoid and neuroendocrine tumors, malignant melanomas, pancreatic, gastrointestinal and lung cancers. Neuroendocrine tumor cell lines of pulmonary and gastrointestinal origin are surprisingly sensitive to PKC delta inhibition by the compounds of the invention. The invention is further directed to methods, compositions and kits containing compounds of the formulas (Ia), (IIa), (IIIa), (IVa), and (V) as disclosed and described in FIGS. 11 and 12.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 19, 2017
    Assignee: Faller & Williams Technology, LLC
    Inventors: Douglas V. Faller, Robert M. Williams
  • Patent number: 9844535
    Abstract: Methods are disclosed herein for administering a oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitor for treating autoimmune and/or glomerulonephritis-associated diseases, and in particular, Systemic Lupus Erythematosus (SLE).
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 19, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Zhong-Yin Zhang, Maria Kontaridis, Li-Fan Zeng, Jianxun Wang
  • Patent number: 9844536
    Abstract: Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: December 19, 2017
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, John Hood
  • Patent number: 9844537
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Presbyopia Therapies LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 9844538
    Abstract: A method of alleviating or treating a condition which can be alleviated or treated by administering hyoscyamine comprises administering to a subject in need thereof a pharmaceutical dosage form which comprises at least one of hyoscyamine and a pharmaceutically acceptable salt thereof. The dosage form comprises two or more hyoscyamine formulations, at least one of the formulations being an immediate release formulation and at least one other one being a controlled release formulation.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 19, 2017
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Viswanathan Srinivasan, Ralph Brown, David Brown, Himanshu Patel, Juan Carlos Menendez, Somphet Peter Suphasawud
  • Patent number: 9844539
    Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 19, 2017
    Assignee: Plexxikon Inc.
    Inventors: Guoxian Wu, Jiazhong Zhang, Yong-Liang Zhu, Chao Zhang, Prabha N. Ibrahim, Songyuan Shi, Wayne Spevak, Dean R. Artis, James Tsai
  • Patent number: 9844540
    Abstract: Provided are methods for treating cancer in a patient by administering at least antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 19, 2017
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Dror Ben-Asher, Danielle Abramson
  • Patent number: 9844541
    Abstract: Hedgehog pathway modulators, such as hedgehog pathway activators or inhibitors, and the use of such modulators to modulate FSH signaling are described.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: December 19, 2017
    Assignee: Strasspharma, LLC
    Inventors: John Strasswimmer, Steven Ory
  • Patent number: 9844542
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: December 19, 2017
    Assignee: Vanderbilt University
    Inventors: Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn, Andrew S. Felts, Alice L. Rodriguez, Katrina A. Smith, Carrie K. Jones
  • Patent number: 9844543
    Abstract: The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: December 19, 2017
    Inventor: Chun-Ching Shih
  • Patent number: 9844544
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 19, 2017
    Assignee: TRIS PHARMA, INC
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 9844545
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: December 19, 2017
    Assignee: TRIS PHARMA, INC.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 9844546
    Abstract: A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF hydroxylase with a substrate. Modulators of HIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 19, 2017
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Patrick Henry Maxwell, Christopher William Pugh, Peter John Ratcliffe, Christopher Joseph Schofield
  • Patent number: 9844547
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: December 19, 2017
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 9844548
    Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: December 19, 2017
    Assignee: ARADIGM CORPORATION
    Inventors: Igor Gonda, James Blanchard, David C. Cipolla
  • Patent number: 9844549
    Abstract: A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic M3 receptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: December 19, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Taisuke Takahashi, Hiroaki Tanaka, Michinori Akaiwa, Kenji Negoro, Hisashi Mihara, Hideyoshi Fuji, Hajime Takamatsu